Novel 5-Azaindole Factor VIIa Inhibitors
[FA7_HUMAN] Defects in F7 are the cause of factor VII deficiency (FA7D) [MIM:227500]. A hemorrhagic disease with variable presentation. The clinical picture can be very severe, with the early occurrence of intracerebral hemorrhages or repeated hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages (epistaxis, menorrhagia) or hemorrhages provoked by a surgical intervention. Finally, numerous subjects are completely asymptomatic despite very low factor VII levels.                       
[FA7_HUMAN] Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium. [TF_HUMAN] Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited protolysis. TF plays a role in normal hemostasis by initiating the cell-surface assembly and propagation of the coagulation protease cascade.
Publication Abstract from PubMed
The discovery and development of 5-azaindole factor VIIa inhibitors will be described.
Novel 5-azaindole factor VIIa inhibitors.,Riggs JR, Hu H, Kolesnikov A, Leahy EM, Wesson KE, Shrader WD, Vijaykumar D, Wahl TA, Tong Z, Sprengeler PA, Green MJ, Yu C, Katz BA, Sanford E, Nguyen M, Cabuslay R, Young WB Bioorg Med Chem Lett. 2006 Jun 15;16(12):3197-200. Epub 2006 Apr 18. PMID:16621549
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.